Myeloid neoplasms in children with sickle cell disease have been rarely reported, and the exact underlying connection between these two conditions is not clearly understood. Whether the acute myeloid leukemia in hydroxyurea-treated sickle cell patients is co-incidental or related to therapy remains an unanswered question. Herein, we report a 14-year-old girl of Haitian descent with sickle beta zero thalassemia on chronic hydroxyurea therapy who developed FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia and underwent a complete disease remission following a combination chemotherapy with sorafenib and was subsequently treated using a T cell replete unmanipulated haploidentical bone marrow transplantation followed by post-transplant cyclophosphamide.
- acute myeloid leukemia
- haploidentical transplantation with post-transplant cyclophosphamide
- hydroxyurea therapy
- sickle cell disease
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health